高级检索
当前位置: 首页 > 详情页

Burden of kidney disease among patients with peritoneal dialysis versus conventional in-centre haemodialysis: A randomised, non-inferiority trial

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Sun Yat Sen Univ, NHC Key Lab Nephrol, Affiliated Hosp 1, Dept Nephrol,Guangdong Prov Key Lab Nephrol, Guangzhou, Peoples R China [2]Nanchang Univ, Affiliated Hosp 1, Dept Nephrol, Nanchang, Jiangxi, Peoples R China [3]Cent South Univ, Xiangya Hosp 3, Dept Nephrol, Changsha, Peoples R China [4]Lanzhou Univ, Hosp 2, Dept Nephrol, Lanzhou, Peoples R China [5]Ningxia Med Univ, Gen Hosp, Dept Nephrol, Yinchuan, Ningxia, Peoples R China [6]Sun Yat Sen Univ, Affiliated Hosp 3, Dept Nephrol, Guangzhou, Peoples R China [7]Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Nephrol, Shanghai, Peoples R China [8]Fujian Med Univ, Affiliated Hosp 1, Dept Nephrol, Fuzhou, Peoples R China [9]Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Nephrol, Tianjin, Peoples R China [10]Jiangxi Prov Peoples Hosp, Dept Nephrol, Nanchang, Jiangxi, Peoples R China [11]Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Dept Nephrol, Chengdu, Peoples R China [12]Shanghai Tenth Peoples Hosp, Dept Nephrol, Shanghai, Peoples R China [13]Dalian Med Univ, Affiliated Hosp 1, Dept Nephrol, Dalian, Peoples R China [14]455th Hosp Chinese Peoples Liberat Army, Dept Nephrol, Shanghai, Peoples R China [15]Soochow Univ, Affiliated Hosp 2, Dept Nephrol, Suzhou, Peoples R China [16]Wuhan 1 Hosp, Dept Nephrol, Wuhan, Peoples R China [17]Shenzhen 2 Peoples Hosp, Dept Nephrol, Shenzhen, Peoples R China [18]Guizhou Prov Peoples Hosp, Dept Nephrol, Guiyang, Peoples R China [19]Guangzhou Panyu Cent Hosp, Dept Nephrol, Guangzhou, Peoples R China [20]Harbin Med Univ, Affiliated Hosp 2, Dept Nephrol, Harbin, Peoples R China [21]Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Nephrol, Shanghai, Peoples R China [22]Guangdong Prov Peoples Hosp, Div Nephrol, 106 Zhongshan Rd 2, Guangzhou 510080, Peoples R China [23]Guangdong Acad Med Sci, 106 Zhongshan Rd 2, Guangzhou 510080, Peoples R China
出处:
ISSN:

关键词: End-stage kidney disease haemodialysis health-related quality of life peritoneal dialysis

摘要:
Background: Little is known about the impact of haemodialysis (HD) and peritoneal dialysis (PD) on health-related quality of life (HRQoL). We compared HRQoL between conventional in-centre HD and home-based PD in 1082 newly diagnosed kidney failure patients. Methods: This was an open-label, randomised, non-inferiority trial of adult patients with a diagnosis of end-stage kidney disease (estimated glomerular filtration rate <= 15 mL/min/1.73 m(2)) requiring maintenance dialysis from 36 sites in China randomised 1:1 to receive PD or conventional in-centre HD. The primary outcome was the 'Burden of Kidney Disease' assessed using the Kidney Disease Quality of Life-Short Form (KDQoL-SF) survey over 48 weeks and the main secondary outcomes were the remaining scales of KDQoL-SF and all-cause mortality. The effect of PD versus HD on the primary outcome was compared by their geometric mean (GM) ratio, and non-inferiority was defined by the lower bound of a one-sided 95% confidence interval (CI) >0.9. Results: A total of 725 subjects completed the trial per protocol (395 PD and 330 HD, mean age 49.8 (standard deviation (SD) 14.4) years, 41.4% women). For the primary outcome, the mean (SD) change in 'Burden of Kidney Disease' over 48 weeks was 2.61 (1.27) in PD group and 2.58 (1.35) in HD group, and the GM ratio (95% CI) was 1.059 (0.908-1.234), exceeding the limit for non-inferiority. For the secondary outcomes, the PD and HD groups were similar in all scales. There were 17 and 31 deaths in PD and HD groups, respectively. Patients receiving PD had more adverse events, adverse event leading to hospitalisation and serious adverse events compared to those allocated to HD, but adverse events leading to death and discontinuation of the trial were not different between PD and HD. Conclusions: In this trial, PD may be non-inferior to HD on the 'Burden of Kidney Disease' among Chinese kidney failure patients who are of younger age and have lower comorbidity after 48 weeks' follow-up.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 4 区 医学
小类 | 4 区 泌尿学与肾脏学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 泌尿学与肾脏学
JCR分区:
出版当年[2020]版:
Q4 UROLOGY & NEPHROLOGY
最新[2023]版:
Q2 UROLOGY & NEPHROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Sun Yat Sen Univ, NHC Key Lab Nephrol, Affiliated Hosp 1, Dept Nephrol,Guangdong Prov Key Lab Nephrol, Guangzhou, Peoples R China
通讯作者:
通讯机构: [1]Sun Yat Sen Univ, NHC Key Lab Nephrol, Affiliated Hosp 1, Dept Nephrol,Guangdong Prov Key Lab Nephrol, Guangzhou, Peoples R China [22]Guangdong Prov Peoples Hosp, Div Nephrol, 106 Zhongshan Rd 2, Guangzhou 510080, Peoples R China [23]Guangdong Acad Med Sci, 106 Zhongshan Rd 2, Guangzhou 510080, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号